Lymphangioleiomyomatosis

2008-10-01   Angelo M Taveira-DaSilva  , Wendy K Steagall  , Joel Moss  

1.Translational Medicine Branch, NHLBI, NIH, Building 10, Room 6D05, MSC 1590, Bethesda, Maryland 20892-1590, USA

Summary

Note

Lymphangioleiomyomatosis (LAM) is a multi-system disease, affecting predominantly pre-menopausal women, that is characterized by proliferation of abnormal smooth muscle-like cells (LAM cells) leading to the formation of lung cysts, fluid-filled cystic tumors in the axial lymphatics (e.g., lymphangioleiomyomas), and abdominal tumors, primarily in the kidneys, comprising adipose cells, vascular structures and LAM cells (e.g., angiomyolipomas).

Clinics and Pathology

Note

Pulmonary disease is the main cause of morbidity and mortality. LAM usually presents with progressive breathlessness or with spontaneous recurrent pneumothorax, chylous effusions (chylothorax and ascites), or hemorrhage within an angiomyolipoma. Computed tomography scans show numerous thin-walled cysts throughout the lungs (Figure 1A and 1B), renal angiomyolipomas (Figure 2), and lymphangioleiomyomas (Figure 3). Pulmonary function abnormalities include airflow obstruction and gas exchange abnormalities.
Lung lesions in LAM are characterized by nodular infiltrates and clusters of LAM cells near cystic lesions and along pulmonary blood vessels, lymphatics, and bronchioles (Figure 4A and 4B). Two types of LAM cells have been described: small spindle-shaped cells and larger, epithelioid-like cells with abundant cytoplasm. Both types of cells react with antibodies against smooth muscle cell-specific antigens (e.g., smooth muscle a-actin, vimentin, desmin) (Figure 5). The epithelioid LAM cells react with HMB-45, a monoclonal antibody that recognizes gp100, a premelanosomal protein (Figures 5, 6 and 7). The spindle-shaped cells are more likely to react with anti-proliferation cell nuclear antigen (PCNA) antibodies, suggesting a more proliferative state. Receptors for estrogen, progesterone, and growth factors have been identified in LAM cells. LAM cells appear to have neoplastic properties and may be capable of metastasis. In addition to their presence in lungs, lymphatics and kidneys, LAM cells have been isolated from blood, chyle, and urine.

Etiology

The tumor suppressor genes TSC1 and TSC2 have been implicated in the etiology of LAM, as mutations and loss of heterozygosity in the TSC genes have been detected in LAM cells (Figure 7). TSC1 encodes hamartin, a protein that plays a role in the reorganization of the actin cytoskeleton, and TSC2 encodes tuberin, a protein with roles in cell growth and proliferation. TSC1 and TSC2 may function both individually and as a cytosolic complex.

Epidemiology

LAM occurs in about one third of women with tuberous sclerosis complex (TSC), an autosomal dominant syndrome characterized by hamartoma-like tumor growths in various organs, cerebral calcifications, seizures, and mental retardation, that occurs in one of 5800 live births. Sporadic LAM is a relatively uncommon disease with a prevalence that has been estimated at 1-2.6/million women.
Atlas Image
Figure 1. Chest CT scan of a patient with LAM (A) showing numerous thin-walled cysts distributed throughout the lungs. (B) The lung parenchyma is almost completely replaced by very small cysts.
Figure 2. Abdominal CT scan of a patient with LAM showing angiomyolipomas involving both kidneys.
Figure 3. Abdominal CT scan of a patient with LAM showing a large lymphangioleiomyoma located in the retroperitoneal area and surrounding the aorta and inferior vena cava.
Figure 4 A and B. LAM nodule comprising spindle-shaped cells and larger epithelioid cells (A). Nodules of various sizes (B) are seen in involved lung (hematoxylin-eosin; original magnification x50).
Figure 5. Immunohistochemistry of LAM cells. Immunoperoxidase method and counterstaining with hematoxylin. A and B: Immunoreactivity with a-smooth muscle actin antibodies. LAM cells show strong reactivity (A). Pulmonary vascular smooth muscle cells are also strongly positive (arrow). LAM cells in the walls of the lung cysts are also strongly reactive (arrow) (B) (original magnification x250 for each). C: Immunoreactivity with monoclonal antibody HMB-45. Immunoreactive cells are distributed in the periphery of LAM lung nodules (arrow) (original magnification x250). D: Immunoreactivity with monoclonal antibody HMB-45. Higher-magnification view of tissue shown in C. A strong granular reaction is present in large epithelioid LAM cells adjacent to epithelial cells covering LAM lung nodules (arrow) (D) (original magnification x1000).
Atlas Image
Figure 6. Left panel: close-up of LAM nodule (hematoxylin-eosin). Right panel: same nodule showing positive immunocytochemistry stain for HMB 45 (original magnification x200).
Figure 7. Characteristics of LAM cells (A-C). Reaction of LAM cells cultured from lung and pulmonary artery smooth muscle cells (PASM) with monoclonal antibody against SMA (A). Reaction of cultured LAM cells and melanoma cells (MALME-3M) with monoclonal antibody HMB-45 (B). Fluorescence in situ hybridization (FISH) for TSC1 (green) and TSC2 (red) in LAM cells showing normal presence of two of each alleles as well as abnormal presence of TSC2 alleles (left) (C). FISH for TSC1 (green, arrow) and TSC2 (red, arrowhead) in LAM cell with one (right) or two TSC2 (left) alleles (C). Bar, 20 µm.

Treatment

Because LAM is predominantly a disease of pre-menopausal women and may worsen during pregnancy, or following the administration of exogenous estrogens, hormonal manipulations have been employed. However, no controlled studies have been undertaken to determine their efficacy. A retrospective study of 275 patients found no difference in disease progression between patients treated with progesterone and patients who received no progesterone. There is also no evidence that suppression of ovarian function, either by oophorectomy or use of gonadotrophin-releasing hormone analogs, benefit patients with LAM.
Progress about the mechanisms regulating cell proliferation and migration, and angiogenesis and lymphangiogenesis, have provided a foundation for the development of new therapies. The mammalian target of rapamycin (mTOR) appears to play a role in regulating the growth and multiplication of LAM cells (Figure 8). An inhibitor of mTOR, sirolimus (rapamycin), an antifungal macrolide antibiotic approved for immunosuppression after solid organ transplantation, has been studied as a possible treatment for LAM. In a rat model of TSC (Eker rat) with a functionally null germline mutation of tsc2, which spontaneously develops renal cell carcinomas, treatment with sirolimus resulted in a decrease in size of kidney tumors by both a reduction in the percentage of proliferating cells, and extensive tumor cell death. An open label study with sirolimus undertaken in twenty patients with angiomyolipomas showed a reduction in tumor size to 53.2+/-26.6 % of baseline at one year. An improvement in some lung function parameters was also observed. A clinical trial [MILES trial (Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus Trial)], to examine the effect of rapamycin on pulmonary function, is underway.
Patients with severe LAM or those who show an accelerated rate of decline in lung function may be referred to a lung transplantation center.

Evolution

LAM is a chronic disease, which may span decades. A retrospective analysis of 402 patients seen at NIH from 1995 to 2006 showed that 22 had died, eight of whom had undergone lung transplantation. The mortality in this large cohort was 5.5%. Of the surviving 380 patients, 38 (10%) had lung transplantation. A recent study reported a ten year survival greater than 90%.

Genes Involved and Proteins

Gene name

TSC1 (Tuberous Sclerosis 1)

Location

9q34.13

Note

TSC1 and TSC2 are tumor suppressor genes. TSC1 (9q34) encodes the 130kDa protein hamartin, while TSC2 (16p13.3) encodes the 200kDa protein tuberin. Hamartin and tuberin may have individual functions, but they also interact to form a cytosolic complex. Loss of heterozygosity of TSC2 has been detected in LAM lesions from lung and kidney, and mutations in TSC2 occur more frequently than those in TSC1 in patients with sporadic LAM. Hamartin may play a role in the reorganization of the actin cytoskeleton, with a lack of hamartin leading to a loss of focal adhesions and detachment from substrate, resulting in cell rounding. Hamartin induces an increase in the levels of RhoGTP , an activator of ERM (ezrin-radixin-moesin) proteins, and binds to activated ERM proteins. ERM proteins bind both filamentous actin and integral membrane proteins, thereby bridging the plasma membrane and cortical actin filaments.
Tuberin has roles in pathways controlling cell growth and proliferation (Figure 8). It is a negative regulator of cell cycle progression, and loss of tuberin function shortens the G1 phase of the cell cycle. Tuberin binds p27KIP1, a cyclin-dependent kinase inhibitor, thereby preventing its degradation and leading to inhibition of the cell cycle. Upon mutation of tuberin, p27 becomes mislocalized in the cytoplasm, allowing the cell cycle to progress.
Tuberin also integrates signals from growth factors and energy stores through its interaction with mTOR (mammalian target of rapamycin) (Figure 8). Tuberin has Rheb GAP (Ras homolog enriched in brain GTPase-activating protein) activity, which converts Rheb-GTP to Rheb-GDP, thereby inactivating Rheb. Rheb controls mTOR, a serine/threonine kinase that phosphorylates at least two substrates: 4E-BP1, allowing cap-dependent translation, and S6K1, leading to translation of 5 TOP (terminal oligopyrimidine tract)-containing RNAs. Phosphorylation of tuberin by Akt, which is known to be activated by growth factors, leads to inhibition of tuberin and results in cell growth and proliferation. Phosphorylation of tuberin by AMPK (AMP-activated kinase) activates tuberin and further promotes inhibition of cell growth in states of energy deprivation.
Tuberin may also have roles in endocytosis through its interaction with rabaptin-5 and in transcriptional activation through interaction with members of the retinoid X receptor (RXR) family.
Atlas Image
Figure 8. Schematic model of TSC1 and TSC2 pathways. The TSC1/TSC2 complex has roles in cell cycle progression and in cell growth and proliferation. Tuberin binds p27KIP1, a cyclin-dependent kinase inhibitor, stabilizing it and resulting in inhibition of cell cycle progression. Tuberin also has Rheb GAP activity, which converts Rheb-GTP to Rheb-GDP, resulting in inactive Rheb. Rheb controls mTOR, which is a kinase that controls translation through the phosphorylation of 4E-BP1 and S6K1. Akt, when activated by growth factors, phosphorylates tuberin, leading to an inhibition of tuberin and resulting in cell growth and proliferation. However, when a state of low cellular energy exists, AMPK phosphorylates tuberin, activating it, and thereby inhibiting cell growth.

Article Bibliography

Pubmed IDLast YearTitleAuthors
21835841990Pulmonary lymphangioleiomyomatosis and steroid receptors. An immunocytochemical study.Berger U et al
126053732003Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis.Bittmann I et al
108239532000Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis.Carsillo T et al
128428882003Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner.Castro AF et al
102082061999Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis.Chu SC et al
108524202000High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex.Costello LC et al
155831382004Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis.Crooks DM et al
82695121993Identification and characterization of the tuberous sclerosis gene on chromosome 16.
115207342001Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis.Franz DN et al
121725552002Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling.Gao X et al
185199732008Lymphatic involvement in lymphangioleiomyomatosis.Glasgow CG et al
120452002002Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM).Goncharova EA et al
180710092008Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis.Harari S et al
96854101998Tuberous sclerosis gene 2 product modulates transcription mediated by steroid hormone receptor family members.Henry KW et al
156240192005Dysregulation of the TSC-mTOR pathway in human disease.Inoki K et al
121725532002TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.Inoki K et al
146518492003TSC2 mediates cellular energy response to control cell growth and survival.Inoki K et al
167074002006Lymphangioleiomyomatosis.Johnson SR et al
125477072003Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplastic and non-neoplastic vascular structures.Karbowniczek M et al
127818662003Tumour suppressors hamartin and tuberin: intracellular signalling.Krymskaya VP et al
108064792000The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho.Lamb RF et al
147293302004TSC2: filling the GAP in the mTOR signaling pathway.Li Y et al
121509152002Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway.Manning BD et al
115642122001Pathogenesis of multifocal micronodular pneumocyte hyperplasia and lymphangioleiomyomatosis in tuberous sclerosis and association with tuberous sclerosis genes TSC1 and TSC2.Maruyama H et al
104607501999Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis.Matsumoto Y et al
182529172008Lymphangioleiomyomatosis: a clinical update.McCormack FX et al
115207352001Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex.Moss J et al
105854431999Characterization of the cytosolic tuberin-hamartin complex. Tuberin is a cytosolic chaperone for hamartin.Nellist M et al
179750022007TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis.Pacheco-Rodriguez G et al
98099731998Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles.Plank TL et al
153518772004Proteins interacting with the tuberous sclerosis gene products.Rosner M et al
182917112008The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners.Rosner M et al
153559972004Tuberin binds p27 and negatively regulates its interaction with the SCF component Skp2.Rosner M et al
162106692006The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment.Ryu JH et al
95293621998Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis.Smolarek TA et al
93610101997Role of the tuberous sclerosis gene-2 product in cell cycle control. Loss of the tuberous sclerosis gene-2 induces quiescent cells to enter S phase.Soucek T et al
115212032001Tuberous sclerosis causing mutants of the TSC2 gene product affect proliferation and p27 expression.Soucek T et al
98610251998Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2.Soucek T et al
176166462007Genetic and morphologic determinants of pneumothorax in lymphangioleiomyomatosis.Steagall WK et al
112086532001The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis.Strizheva GD et al
170755652006Lymphangioleiomyomatosis.Taveira-DaSilva AM et al
122711412002Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.Tee AR et al
129067852003Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb.Tee AR et al
104990731999Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P).Urban T et al
97863501998Immunohistochemical analysis of proteins of the Bcl-2 family in pulmonary lymphangioleiomyomatosis: association of Bcl-2 expression with hormone receptor status.Usuki J et al
90456181997The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis.Xiao GH et al
127719622003Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins.Zhang Y et al
95806711998Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products.van Slegtenhorst M et al

Citation

Angelo M Taveira-DaSilva ; Wendy K Steagall ; Joel Moss

Lymphangioleiomyomatosis

Atlas Genet Cytogenet Oncol Haematol. 2008-10-01

Online version: http://atlasgeneticsoncology.org/solid-tumor/5135/js/gene-explorer/hgnc